Do Traders Think Legend Biotech Corp (LEGN) Can Keep Climbing Monday?

Overall market sentiment has been high on Legend Biotech Corp (LEGN) stock lately. LEGN receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Legend Biotech Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LEGN!

See Full LEGN Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With LEGN Stock Today?

Legend Biotech Corp (LEGN) stock is lower by -0.86% while the S&P 500 is up 2.89% as of 3:21 PM on Monday, Oct 3. LEGN has fallen -$0.35 from the previous closing price of $40.80 on volume of 469,912 shares. Over the past year the S&P 500 is down -14.21% while LEGN has fallen -20.62%. LEGN lost -$2.34 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Legend Biotech Corp click here.

More About Legend Biotech Corp

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from North America. Click Here to get the full Stock Report for Legend Biotech Corp stock.